Physician-scientists at Groupe de Recherche Action en Santé (GRAS) in Burkina Faso have successfully completed initial safety evaluations in 30 adult Burkinabés as the first phase of a clinical trial of Sanaria PfSPZ-LARC2 Vaccine, which is designed to prevent infection with Plasmodium falciparum malaria.